Q4 2024 Viatris Inc Earnings Call Transcript
Key Points
- Viatris Inc (VTRS) achieved a full year revenue growth of 2% on a divestiture adjusted operational basis, aligning with their guidance.
- The company successfully returned approximately $825 million to shareholders through dividends and share repurchases.
- Viatris Inc (VTRS) retired approximately $3.7 billion of debt, achieving their long-term gross leverage target.
- The company expanded its innovative portfolio with three new products: Selatogrel, Cenerimod, and Sotagliflozin.
- Viatris Inc (VTRS) reported strong free cash flow of approximately $2.6 billion, excluding divestiture-related taxes and transaction costs.
- The FDA issued a warning letter and import alert for Viatris Inc (VTRS)'s facility in Indore, India, impacting 11 actively distributed products in the US.
- The company anticipates a negative impact on 2025 total revenues of approximately $500 million due to the Indore facility issues.
- The Indore situation is expected to negatively impact 2025 adjusted EBITDA by approximately $385 million.
- Viatris Inc (VTRS) expects total revenues to decline approximately 1% in 2025, primarily due to the Indore facility issues.
- The company faces potential competition and price erosion in North America, affecting certain generics like Xulane and others.
Good morning, everyone, and welcome to the Viatris Q4 and full year 2024 earnings call. (Operator Instructions)
Please also note today's event is being recorded. At this time, I'd like to turn the conference call over to Bill Szablewski, Head of Capital Markets. Sir, please go ahead.
Good morning, everyone. Welcome to our Q4 2024 earnings call. With us today is our CEO, Scott Smith; CFO, Doretta Mistras; Chief R&D Officer, Philippe Martin; and Chief Commercial Officer Corinne Le Goff.
During today's call, we'll be making forward-looking statements on a number of matters, including our financial guidance for 2025 and various strategic initiatives. These statements are subject to risk and uncertainties. We will also be referring to certain actual and projected non-GAAP financial measures. Please refer to today's slide presentation and our SEC filings for more information, including reconciliations of those non-GAAP measures to the most directly comparable GAAP measures.
When
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
